Reviewing Nemaura Medical (NASDAQ:NMRD) & DexCom (NASDAQ:DXCM)

Nemaura Medical (NASDAQ:NMRD) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Profitability

This table compares Nemaura Medical and DexCom’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
DexCom	17.22%	31.40%	10.58%

Analyst Recommendations

This is a summary of recent ratings and target prices for Nemaura Medical and DexCom, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
DexCom	0	6	11	1	2.72

DexCom has a consensus price target of $104.59, suggesting a potential upside of 34.57%. Given DexCom’s stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Nemaura Medical.

Insider and Institutional Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Nemaura Medical has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nemaura Medical and DexCom”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	0.00	-$14.14 million	($0.39)	N/A
DexCom	$3.62 billion	8.38	$541.50 million	$1.67	46.54

DexCom has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Summary

DexCom beats Nemaura Medical on 12 of the 13 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.